ABSTRACT. Vitronectin is a 75 kilodalton (kDa) cell-adhesive glycoprotein found in animal blood and connective tissue, also termed serum spreading factor, S-protein, and epibolin. It promotes attachment and spreading of animal cells on tissue culture dishes, and it also binds to collagen. We established four mouse hybridoma lines producing monoclonal antibodies (M1, M2, M4 and M5) to human vitronectin. By immunoblotting, both epitopes recognized by M4 and M5 were suggested to exist in the amino terminal 5 kDa portion of vitronectin, and both Ml and M2 bound to the adjacent 35 kDa portion. Cell spreading on vitronectin-coated dishes was inhibited by M4 = M5 > M1, but not by M2. Collagen binding to vitronectin was inhibited by M2 >M4 =M5, but not by M1. These results indicate that the collagen-binding site is located near the cellbinding site in the amino terminal half of vitronectin. Independent inhibition of vitronectin binding to the cell and to collagen by these monoclonal antibodies will provide a potential tool to dissect the structure and function of vitronectin.
Vitronectin is a cell-adhesive glycoprotein found in animal blood and connective tissue (4, 7, 9, 14) , also termed serum spreading factor (3), S-protein (16) , and epibolin (18) . Since vitronectin promotes the attachment and spreading of a variety of animal cells on tissue culture dishes, it is assumed that vitronectin as well as fibronectin (10, 22) are the major cell-attachment factors in the animal serum used for tissue culture. Furthermore, vitronectin also functions in blood coagulation (5, 11, 17) and complement action (16) . In connective tissues, vitronectin exists as one of extracellular matrix proteins, probably interacting with cells directly or associating with heparin-like glycosaminoglycans and collagens, which are reported to bind to vitronectin in vitro (1, 6, 9) .
The entire primary structure of vitronectin has been deduced from its cDNA (13, 19) . One amino acid sequence in the cell-binding site was determined to be ArgGly-Asp and is located near the amino terminus (19, 20) . The heparin-binding site which is cryptic in the native form of vitronectin (2, 8) is located, on the other hand, near the carboxyl terminus (20) .
Gebb et al. (6) first reported on the binding of vitronectin to native collagens, but + To whom correspondence should be addressed. along with a few other molecular weight fragments ( Fig. 2A) . According to the results of Suzuki et al. (20) , the 40 kDa fragment includes the amino terminus of vitronectin, whereas the 32 kDa fragment is located in the carboxyl terminal half of vitronectin and does not share any portion with the above 40 kDa fragment. The entire 26 kDa fragment is included in the 32 kDa fragment. All of monoclonal antibodies, Ml , M2, M4, and M5, selectively reacted with the 40 kDa fragment as well as uncleaved 75 kDa and 65 kDa vitronectin, but they reacted with neither the 32 kDa fragment nor the 26 kDa fragment.
To determine more precisely the location of their epitopes, the binding of the antibodies to CNBr fragments of vitronectin was examined. CNBr treatment of vitronectin produced 53 kDa, 43 kDa, and 35 kDa fragments. According to the results of Suzuki et al. (20) , the 53 kDa fragment includes the entire 43 kDa fragment, which in turn includes the entire 35 kDa fragment. Both the 43 kDa and 35 kDa fragments lack the amino terminal 5 kDa portion of vitronectin whereas the 53 kDa fragment retains it. Immunoblotting with the antibodies showed that both M4 and M5 selectively reacted with the 53 kDa fragment, but not with the 43 kDa and 35 kDa fragments. On the other hand, both Ml and M2 reacted not only with the 53 kDa fragment, but also with the 43 kDa and 35 kDa fragments (Fig. 2B) . These results suggest that the epitopes for M4 and M5 exist in the 5 kDa portion at the amino terminus of vitronectin, and that M1 and M2 recognize epitopes existing in the adjacent 35 kDa portion. Inhibition of cell-spreading by antibodies. The cell-binding site of vitronectin is known to be located in the amino terminal 5 kDa portion (13, 19, 20) . The four monoclonal antibodies as well as a polyclonal antibody were tested to see whether M1 in the binding of vitronectin to collagen is suspected to be due to M1 's own properties and not due to the use of lower doses.
Assuming that the monoclonal antibodies do not induce a conformational change in vitronectin, the binding site for the cell and that for collagen cannot be mapped on a one-dimensional linear model of vitronectin. The model needs a two-dimensional structure, in which the cell-binding site near the amino terminus is proposed to turn back on itself. To satisfy the above requirements, we have diagrammed two possible two-dimensional models of vitronectin with the arrangement of cellbinding and collagen-binding sites as shown in Fig. 5. In model (A) , the proximity between the collagen-binding site and cell-binding site is achieved by placing them close together in the one-dimensional primary structure of vitronectin. In model (B), on the other hand, the two binding sites are distant to each other in the primary structure, but exist close together due to polypeptide folding. To establish which model in Fig. 5 is correct, further experiments including isolation of the collagenbinding domain would be advisable. These models support Preissner's model of vitronectin based on computer analysis of the amino acid sequence, in which the amino terminal portion folds into the vitronectin molecule (17) .
We have confirmed the binding of vitronectin to type I collagen originally reported by Gebb et al. (6) . They reported that higher than physiological salt concentrations interfere with the binding of vitronectin to collagen. However, in our hands, binding was remarkably inhibited even by physiological concentrations of NaCl. Therefore, the interaction between vitronectin and collagen may not be physiological. If it is, the interaction does not seem to be strong in vivo.
M4 and M5 inhibited both the cell spreading and collagen binding activities of vitronectin. However, M1 specifically inhibited the cell spreading activity and M2 specifically inhibited the collagen binding activity. These function-specific monoclonal anti-vitronectin antibodies are described in this paper for the first time, and as specific functional inhibitors, they will provide a strong tool in the clarification of the molecular mechanisms and biological functions of vitronectin in vivo as well as in vitro.
